Confirmatory Phase III Clinical Study
DIA-AID 2 (DiaPep277® - Arresting Immune Diabetes)
DIA-AID 2 is a confirmatory phase III study which is ongoing. This study is a global clinical trial which is being conducted at more than 120 clinical study sites. Patient recruitment has been completed and the study is expected to be completed at the end of 2014.
Eligible patients for the study are between 20 to 45 years of age and within 6 months of diagnosis of type 1 diabetes. Furthermore, the study requires a residual beta cell function when fasting of C-peptide ≥ 0.2nmol/L.
Patients are randomized to 1.0 mg DiaPep277® or placebo with primary endpoint beta cell preservation of function.
Study Steering Committee
Click on a flag below to find a clinical study site near you.
- Prof. Itamar Raz
Hadassah Medical Center
- Prof. Paolo Pozzilli
Università Campus Bio-Medico di Roma
- Prof. Thomas Linn
- Prof. Francois Bonnici
New Groote Schuur Hospital
Capetown, South Africa
- Prof. Philip Raskin
University of Texas Southwestern Medical Center at Dallas